Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMY0QL7)

Drug Name

Iomab-ACT Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell acute lymphoblastic leukaemia	2B33.3	Phase 1	[1]
Diffuse large B-cell lymphoma	2A81	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte common antigen (PTPRC)	TTUS45N	PTPRC_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Leukocyte common antigen (PTPRC)	DTT	PTPRC	6.121	6.524	4.548	6.619

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

B-cell acute lymphoblastic leukaemia

ICD Disease Classification

2B33.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Leukocyte common antigen (PTPRC)	DTT	PTPRC	5.86E-05	-0.26	-0.36

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04512716) Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.